Education
About Us
Working with TipRanks
Follow Us
Conmed (CNMD)
NYSE:CNMD
CNMD Stock Chart & Stats
$44.35
$0.19(0.28%)
At close: 4:00 PM EST
$44.35
$0.19(0.28%)
Day’s Range― - ―
52-Week Range$38.32 - $74.70
Previous CloseN/A
Volume49.43K
Average Volume (3M)368.83K
Market Cap
$1.29B
Enterprise Value$2.10B
Total Cash (Recent Filing)$38.93M
Total Debt (Recent Filing)$853.75M
Price to Earnings (P/E)20.2
Beta0.47
Next Earnings
Jan 28, 2026EPS Estimate
1.32Next Dividend Ex-DateN/A
Dividend Yield2.02%
Share Statistics
EPS (TTM)1.08
Shares Outstanding30,967,955
10 Day Avg. Volume284,080
30 Day Avg. Volume368,831
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.19
Price to Sales (P/S)1.62
P/FCF Ratio13.72
Enterprise Value/Market Cap1.63
Enterprise Value/Revenue1.56
Enterprise Value/Gross Profit2.88
Enterprise Value/Ebitda10.98
Forecast
1Y Price Target
$50.00Price Target Upside12.74% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross Margin ImprovementCompany guidance and analyst adjustments indicate the transaction will be accretive to gross margin, with management citing about 80 basis points of margin benefit from the deal.
Management Transition ContinuityDeparting CFO remaining in an advisory role is intended to ensure continuity in financial reporting and ease the leadership transition for investors and stakeholders.
Portfolio OptimizationCNMD's announced exit from its gastroenterology product lines refocuses company resources on higher-margin and growth-oriented segments, supporting expectations for stronger strategic positioning.
Bears Say
Earnings Dilution RiskThe gastroenterology exit, while margin-accretive, is expected to reduce adjusted earnings per share in 2026, creating concern about near-term earnings dilution.
Guidance Below ExpectationsCompany financial guidance coming in below analyst consensus increases downside risk as investors reassess forward revenue and profitability expectations.
Leadership And Communication UncertaintyCFO departure with no timeline for a permanent replacement and limited commentary on the quarter heightens uncertainty around financial leadership and investor communication.
Conmed News
CNMD FAQ
What was Conmed’s price range in the past 12 months?
Conmed lowest stock price was $38.32 and its highest was $74.70 in the past 12 months.
What is Conmed’s market cap?
Conmed’s market cap is $1.29B.
When is Conmed’s upcoming earnings report date?
Conmed’s upcoming earnings report date is Jan 28, 2026 which is in 9 days.
How were Conmed’s earnings last quarter?
Conmed released its earnings results on Nov 05, 2025. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.062 by $0.018.
Is Conmed overvalued?
According to Wall Street analysts Conmed’s price is currently Undervalued.
Does Conmed pay dividends?
Conmed pays a Quarterly dividend of $0.2 which represents an annual dividend yield of 2.02%. See more information on Conmed dividends here
What is Conmed’s EPS estimate?
Conmed’s EPS estimate is 1.32.
How many shares outstanding does Conmed have?
Conmed has 30,967,955 shares outstanding.
What happened to Conmed’s price movement after its last earnings report?
Conmed reported an EPS of $1.08 in its last earnings report, beating expectations of $1.062. Following the earnings report the stock price went down -0.518%.
Which hedge fund is a major shareholder of Conmed?
Currently, no hedge funds are holding shares in CNMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Conmed Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$50.00 (12.74% Upside)
$50.00 (12.74% Upside)
Hedge Fund Trend
Increased
By 106.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $268.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.21%
12-Months-Change
Fundamentals
Return on Equity
6.60%
Trailing 12-Months
Asset Growth
1.87%
Trailing 12-Months
Company Description
Conmed
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
CNMD Company Deck
CNMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and strategic initiatives aimed at improving long-term profitability and shareholder value. However, challenges such as tariff impacts on margins and a significant decrease in GAAP net income were noted. The shift in capital allocation from dividends to share repurchases indicates a strategic focus on enhancing financial flexibility.View all CNMD earnings summariesCNMD Stock 12 Month Forecast
Average Price Target
$50.00
▲(12.74% Upside)
Technical Analysis
Artivion
―
Integra Lifesciences
―
Ufp Technologies
―
AdaptHealth
―
PROCEPT BioRobotics
―
Ownership Overview
Currently, No data available
---